Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaWAR:SPH 67 Receivables Turnover is 1.63 as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.38 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 117 Medical Distribution companies, Sopharma AD-Sofia ranks better than 71.79% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sopharma AD-Sofia's Revenue for the
three
months ended in Mar. 2026 was zł1,548 Mil. Sopharma AD-Sofia's average Accounts Receivable for the
three
months ended in Mar. 2026 was zł948 Mil.
Hence, Sopharma AD-Sofia's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.63.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sopharma AD-Sofia Receivables Turnover Related Terms
Sopharma AD-Sofia Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Receivables Turnover Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a Receivables Turnover of 1.63 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #33 out of 117 companies in the Medical Distribution industry, placing it in the top 28.2%.
Is Sopharma AD-Sofia's Receivables Turnover too high?
Sopharma AD-Sofia's current Receivables Turnover is 1.63. The Medical Distribution industry median Receivables Turnover is 4.55. Sopharma AD-Sofia's value of 1.63 is 64.2% below this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #33 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Receivables Turnover compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #33 out of 117 companies for Receivables Turnover. This puts Sopharma AD-Sofia in the upper half of its industry. The industry median Receivables Turnover is 4.55. Sopharma AD-Sofia's value of 1.63 is 64.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Receivables Turnover of 1.63 is 64.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Receivables Turnover is 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.38, compared to a current price of zł7.56 — trading 43.5% below its estimated fair value. The current Receivables Turnover is 1.63 and 64.2% below the Medical Distribution industry median of 4.55. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Receivables Turnover is 1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.56 is trading 43.5% below its estimated GF Value™ of zł13.38.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Receivables Turnover: 1.63
GF Value™: zł13.38 vs. price of zł7.56 (43.5% below fair value)
Industry Position: 64.2% below the Medical Distribution median (#33 of 117)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
